Atrial fibrillation (AF)

Diagnostic and therapeutic approach

Edoxaban (Lixiana)



60 mg / day or 30 mg / day if renal impairment or weight <60 kg.

Absolute contra-indications

  • Hypersensitivity to the active substance or to any of the excipients.
  • Acute hemorrhage, clinically significant.
  • Patients with hepatic disease associated with coagulopathy and a risk of significant bleeding.
  • Injury or illness, if considered at significant risk of major bleeding.
  • Pregnancy and breast feeding.
  • Attention to drug interactions and inhibitors of CYP3A4 and / or P-gp.